TSO3 http://www.tso3.com/en/ en-ca Copyright 2008 daily TSO3 realizes its highest revenues during the second quarter of 2008 http://www.tso3.com/en/news-events/news-tso3-realizes-its-highest-237.php Highlights from the second quarter 2008:  The Company recorded its highest revenues for a one-quarter period;  Implementation of measures that will significantly reduce the Company's operating costs;  Certification by the U.S. General Services Administration, opening up a market of 225 health establishments in the United States;  Agreement with a U.S. firm specialized in financing medical equipment purchases;  Recruitment of new R&D resources and improved alignment of the technological development program with market needs;  U.S. registration of the “SteriZone®” brand name for TSO3’s 125L ozone sterilizer. Quebec, August 1, 2008 – Mr. W. Barry McDonald, Interim President and Chief Executive Officer of TSO3 Inc. (“TSO3”) (TSX: TOS), is pleased to announce that the Company realized its highest revenues over a one-quarter period during the three-month period ended June 30, 2008, with six units (three in Canada and three in the United States). The Company recorded revenues of $1.0 million during the second quarter, compared to revenues of $575,253 for the same period last year. “These results indicate the Company has gained some traction with its revised strategy of re-focussing its marketing and sales resources. We are confident that the sales made during the second quarter represent the beginning of a more consistent sales trend for the Company,” said Mr. McDonald. Commercial development: several major achievements Among the recent highlights on the commercial level, was the accreditation obtained by TSO3 with the U.S. General Services Administration. This enables the Company to sell its sterilizer to some 225 U.S. Government healthcare facilities, in particular, hospitals and medical centres for military personnel, veterans and Native Americans. “This achievement is in line with our refocusing strategy announced June 5, 2008. In priority, this strategy targets select high-potential market segments for TSO3, including North American hospitals and medical centres. We also anticipate that we will enter other potential market segments for TSO3 in the United States, such as the medical equipment manufacturing sector that will offer potential multi-product buyers,” added Mr. McDonald. In other regions of the world, the Company intends to adopt an opportunistic approach and take advantage of eventual business development opportunities, notably for their ability to generate short-term revenues. In addition, with the goal of driving interest in TSO3's offering and easing the acquisition process, the Company has entered into an agreement with a U.S. firm specialized in medical equipment purchase financing. By taking advantage of this offer, the Company's clients will not have to pay out the full purchase price in one lump sum, yet they will be able to immediately begin benefiting from the operational savings generated by TSO3's 125L ozone sterilizer. Furthermore, another important highlight in recent weeks for TSO3 is the U.S. registration of its new brand name “SteriZone®” for its 125L ozone sterilizer. This new, simple and descriptive name should contribute toward increasing product recognition and awareness of this sterilizer in the Company’s target markets. R&D operational efficiency With regard to R&D operations, the Company has recently created a new R&D Director position and hired new personnel in this department. The Company is now equipped with a more complete team that has the expertise required to carry out the objectives of our technological development program and more proactively address market expectations. Furthermore, in recent months TSO3 has been able to increase its operational performance and reduce its operating costs. This is in line with the objectives set early last May. As a result, the burn-rate will be reduced in the coming quarters, without impacting business and technological development effectiveness. In order to ensure more efficient implementation and better resource allocation to manage all operations, TSO3 has also recently appointed an Operations Director. “This new position will allow Simon Robitaille, our Co-Founder, Vice-President Operations / R&D, Chief Scientific Officer who previously had responsibility for operations, to exclusively focus his time and energy on carrying out new technological development programs – one of our main priorities and the cornerstone of our future success,” said Mr. McDonald. Through these initiatives implemented in recent weeks, TSO3’s objectives are to increase short and long-term sales; notably by a reduction in the sales cycle time, better align our technology to market needs; and make optimal use of our financial resources via efficiency gains and operating cost reductions. “Today, we can affirm that TSO3 is a more efficiently structured enterprise and that we will be better positioned to identify and take advantage of potential business opportunities,” concluded Mr. McDonald. Conference call TSO3 will host a telephone conference call this Friday, August 1, at 11:00 a.m. (EST) related to the publication of its second quarter results. Analysts and institutional investors are invited to participate in this call. Please dial (514) 807-8791 (Montreal region), (416) 644-3416 (Toronto region) or the toll-free number 1-800 732-9303. Journalists, or anyone else interested in listening to the conference call in real time, can do so via a webcast accessible through TSO3’s website at: www.tso3.com. The webcast will be archived for 90 days. To view the full announcement, click here. The full financial results will soon be available in the Investor's section of our Website. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company’s Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Marc Boisjoli CFO (418) 651-0003, ext. 228 mboisjoli@tso3.com Frédéric Tremblay HKDP Tel.: 514 395-0375, ext. 234 Highlights from the second quarter 2008:

 The Company recorded its highest revenues for a one-quarter period;

 Implementation of measures that will significantly reduce the Company's operating costs;

 Certification by the U.S. General Services Administration, opening up a market of 225 health establishments in the United States;

 Agreement with a U.S. firm specialized in financing medical equipment purchases;

 Recruitment of new R&D resources and improved alignment of the technological development
program with market needs;

 U.S. registration of the “SteriZone®” brand name for TSO3’s 125L ozone sterilizer.


Quebec, August 1, 2008 – Mr. W. Barry McDonald, Interim President and Chief Executive Officer of TSO3 Inc. (“TSO3”) (TSX: TOS), is pleased to announce that the Company realized its highest revenues over a one-quarter period during the three-month period ended June 30, 2008, with six units (three in Canada and three in the United States). The Company recorded revenues of $1.0 million during the second quarter, compared to revenues of $575,253 for the same period last year.

“These results indicate the Company has gained some traction with its revised strategy of re-focussing its marketing and sales resources. We are confident that the sales made during the second quarter represent the beginning of a more consistent sales trend for the Company,” said Mr. McDonald.

Commercial development: several major achievements

Among the recent highlights on the commercial level, was the accreditation obtained by TSO3 with the U.S. General Services Administration. This enables the Company to sell its sterilizer to some 225 U.S. Government healthcare facilities, in particular, hospitals and medical centres for military personnel, veterans and Native Americans. “This achievement is in line with our refocusing strategy announced June 5, 2008. In priority, this strategy targets select high-potential market segments for TSO3, including North American hospitals and medical centres. We also anticipate that we will enter other potential market segments for TSO3 in the United States, such as the medical equipment manufacturing sector that will offer potential multi-product buyers,” added Mr. McDonald.

In other regions of the world, the Company intends to adopt an opportunistic approach and take advantage of eventual business development opportunities, notably for their ability to generate short-term revenues.

In addition, with the goal of driving interest in TSO3's offering and easing the acquisition process, the Company has entered into an agreement with a U.S. firm specialized in medical equipment purchase financing. By taking advantage of this offer, the Company's clients will not have to pay out the full purchase price in one lump sum, yet they will be able to immediately begin benefiting from the operational savings generated by TSO3's 125L ozone sterilizer.

Furthermore, another important highlight in recent weeks for TSO3 is the U.S. registration of its new brand name “SteriZone®” for its 125L ozone sterilizer. This new, simple and descriptive name should contribute toward increasing product recognition and awareness of this sterilizer in the Company’s target markets.

R&D operational efficiency

With regard to R&D operations, the Company has recently created a new R&D Director position and hired new personnel in this department. The Company is now equipped with a more complete team that has the expertise required to carry out the objectives of our technological development program and more proactively address market expectations.

Furthermore, in recent months TSO3 has been able to increase its operational performance and reduce its operating costs. This is in line with the objectives set early last May. As a result, the burn-rate will be reduced in the coming quarters, without impacting business and technological development effectiveness.

In order to ensure more efficient implementation and better resource allocation to manage all operations, TSO3 has also recently appointed an Operations Director. “This new position will allow Simon Robitaille, our Co-Founder, Vice-President Operations / R&D, Chief Scientific Officer who previously had responsibility for operations, to exclusively focus his time and energy on carrying out new technological development programs – one of our main priorities and the cornerstone of our future success,” said Mr. McDonald.

Through these initiatives implemented in recent weeks, TSO3’s objectives are to increase short and long-term sales; notably by a reduction in the sales cycle time, better align our technology to market needs; and make optimal use of our financial resources via efficiency gains and operating cost reductions. “Today, we can affirm that TSO3 is a more efficiently structured enterprise and that we will be better positioned to identify and take advantage of potential business opportunities,” concluded Mr. McDonald.

Conference call

TSO3 will host a telephone conference call this Friday, August 1, at 11:00 a.m. (EST) related to the publication of its second quarter results. Analysts and institutional investors are invited to participate in this call. Please dial (514) 807-8791 (Montreal region), (416) 644-3416 (Toronto region) or the toll-free number 1-800 732-9303.

Journalists, or anyone else interested in listening to the conference call in real time, can do so via a webcast accessible through TSO3’s website at: www.tso3.com. The webcast will be archived for 90 days.

To view the full announcement, click here.

The full financial results will soon be available in the Investor's section of our Website.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment.

In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company’s Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

- 30 -

Source: TSO3 Inc.

Information: Marc Boisjoli
CFO
(418) 651-0003, ext. 228
mboisjoli@tso3.com
Frédéric Tremblay
HKDP
Tel.: 514 395-0375, ext. 234
]]> TSO3 realizes its highest revenues during the second quarter of 2008 2008-08-01 08:36:34 TSO3: Conference Call and Webcast - Financial Results for Q2 2008 http://www.tso3.com/en/news-events/news-tso3-conference-call-webcast-236.php Quebec City, Quebec, Canada, July 17, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) today announced that it will report financial results for the second quarter 2008 ended June 30, 2008, on Friday, August 1, 2008. TSO3 will host a Conference Call at 11:00 A.M. (ET), on August 1, 2008. Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), (416) 644-3416 (Toronto area) or the toll-free number 1 800 732-9303. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's Website at: www.tso3.com. The Webcast will be archived for 90 days. As previously announced, from now on, the sales realized by the Company during the normal course of its operations will be disclosed within the quarterly results report. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company’s Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Marc Boisjoli CFO (418) 651-0003, ext. 228 mboisjoli@tso3.com Frédéric Tremblay HKDP Tel.: 514 395-0375, ext. 234 Quebec City, Quebec, Canada, July 17, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) today announced that it will report financial results for the second quarter 2008 ended June 30, 2008, on Friday, August 1, 2008. TSO3 will host a Conference Call at 11:00 A.M. (ET), on August 1, 2008.

Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), (416) 644-3416 (Toronto area) or the toll-free number 1 800 732-9303. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's Website at: www.tso3.com. The Webcast will be archived for 90 days.

As previously announced, from now on, the sales realized by the Company during the normal course of its operations will be disclosed within the quarterly results report.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment.

In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company’s Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

- 30 -

Source: TSO3 Inc.

Information: Marc Boisjoli
CFO
(418) 651-0003, ext. 228
mboisjoli@tso3.com

Frédéric Tremblay
HKDP
Tel.: 514 395-0375, ext. 234
]]> TSO3: Conference Call and Webcast - Financial Results for Q2 2008 2008-07-17 08:37:37 TSO3 Refocuses its Marketing Activities to Accelerate Sales and Revenue Growth http://www.tso3.com/en/news-events/news-tso3-refocuses-its-marketing-235.php Quebec City, Quebec, Canada, June 5, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces that it is realigning resources and re-focusing marketing activities to enhance its rate of market penetration and sales growth for 2008 and beyond. These initiatives will also allow the Company to significantly reduce its operating expenses rate thanks to more efficient use of sales and marketing resources. Initiatives impact four areas: (1) market segmentation of the primary North American hospital market, using a contracted specialized US marketing firm in conjunction with direct selling resources; (2) realign sales resources to more effectively focus its senior sales management team on targets in the pipeline and sales leads; (3) reducing cash burn rate for 2008 by $2.1 million; (4) assessing and prioritizing R&D projects with resource additions as needed. Additionally, TSO3 will be analysing other near term sales opportunities for its 125L Ozone Sterilizer by evaluating other territories or market sectors, such as other countries and medical device companies, which offer pre-sterilized products to the market. TSO3 is already seeing early indications of momentum from these recent initiatives with several target accounts pending purchase decisions. “These new measures should allow us to generate sales momentum to achieve our expected sales forecast, while attaining a net effect of cash burn rate reduction of $2.1M for the remainder of the year”, stated W. Barry McDonald, Interim CEO for TSO3. “This re-focusing and realigning is being done with the intent of maximising the very capable sales resources that we have on board at management level, to generate sales in the very short term and ensure business growth in 2008 and beyond”. TSO3 plans to give an update on the progress of these initiatives and provide further quantitative financial information on its reduced operating expenses, on or before its next quarterly release in early August. Moreover, from now on, the sales realized by the Company during the normal course of its operations will be disclosed within the quarterly results report. Conference call TSO3 will host a Conference Call at 11:00 A.M. (ET), on June 6, 2008. Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3415 (Toronto area) or the toll-free number 1 800 733-7560. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3’s Website at: www.tso3.com The Webcast will be archived for 90 days. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company’s Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Marc Boisjoli CFO (418) 651-0003, Ext. 228 mboisjoli@tso3.com Frédéric Tremblay HKDP Tel.: 514 395-0375, Ext. 234 Quebec City, Quebec, Canada, June 5, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces that it is realigning resources and re-focusing marketing activities to enhance its rate of market penetration and sales growth for 2008 and beyond. These initiatives will also allow the Company to significantly reduce its operating expenses rate thanks to more efficient use of sales and marketing resources.

Initiatives impact four areas: (1) market segmentation of the primary North American hospital market, using a contracted specialized US marketing firm in conjunction with direct selling resources; (2) realign sales resources to more effectively focus its senior sales management team on targets in the pipeline and sales leads; (3) reducing cash burn rate for 2008 by $2.1 million; (4) assessing and prioritizing R&D projects with resource additions as needed. Additionally, TSO3 will be analysing other near term sales opportunities for its 125L Ozone Sterilizer by evaluating other territories or market sectors, such as other countries and medical device companies, which offer pre-sterilized products to the market.

TSO3 is already seeing early indications of momentum from these recent initiatives with several target accounts pending purchase decisions.

“These new measures should allow us to generate sales momentum to achieve our expected sales forecast, while attaining a net effect of cash burn rate reduction of $2.1M for the remainder of the year”, stated W. Barry McDonald, Interim CEO for TSO3. “This re-focusing and realigning is being done with the intent of maximising the very capable sales resources that we have on board at management level, to generate sales in the very short term and ensure business growth in 2008 and beyond”.

TSO3 plans to give an update on the progress of these initiatives and provide further quantitative financial information on its reduced operating expenses, on or before its next quarterly release in early August. Moreover, from now on, the sales realized by the Company during the normal course of its operations will be disclosed within the quarterly results report.

Conference call

TSO3 will host a Conference Call at 11:00 A.M. (ET), on June 6, 2008. Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3415 (Toronto area) or the toll-free number 1 800 733-7560.

Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3’s Website at: www.tso3.com The Webcast will be archived for 90 days.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment.

In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company’s Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

- 30 -

Source: TSO3 Inc.

Information: Marc Boisjoli
CFO
(418) 651-0003, Ext. 228
mboisjoli@tso3.com

Frédéric Tremblay
HKDP
Tel.: 514 395-0375, Ext. 234
]]> TSO3 Refocuses its Marketing Activities to Accelerate Sales and Revenue Growth 2008-06-05 09:09:18 NEWS FLASH - TSO3 Receives National Recognition for its Environmental Initiatives http://www.tso3.com/en/news-events/news-news-flash-tso3-receives-234.php Québec City, Canada, May 23, 2008 – TSO3 Inc. (www.tso3.com) has received the Champions for Change award from Practice Greenhealth (PGH), formerly Hospitals for a Healthy Environment (H2E), for the improvements made to its product for lower power requirements. This allows TSO3 to reduce the environmental footprint of its 125L Ozone Sterilizer and therefore, to assist its customers in improving their environmental performance. “This award is a reflection of TSO3’s business ethics and represents a strong commitment to protect patient health and preserve the environment,” said Bob Jarboe, Executive Director, Practice Greenhealth. “The stakes are high and TSO3 has shown us their solutions are exciting.” With this award, TSO3 gets recognition for its environmental initiatives for a second year in a row. In 2007, TSO3 was awarded the “Venture Green” mention at the 2007 OHA HealthAchieve show, held in Toronto for over 8,000 Healthcare Professionals. “TSO3 recognizes the importance of providing quality medical products that also contribute to a better environment as one of our corporate commitments,” said W. Barry McDonald, Interim CEO for TSO3. “Many healthcare facilities are asking for eco-friendly, non-toxic products that eliminate/reduce the bio-hazard impact on employees and the environment. We are pleased to be delivering a unique sterilizer that can positively impact both the environment and public health. We are also pleased to receive this award as a confirmation of our commitment for better patient care with environmentally safe products.” Practice Greenhealth presented Environmental Excellence awards to 140 organizations for their work and commitment to health care and the environment. The Awards were held on the first day of CleanMed 2008, a global conference for environmental leaders in health care, taking place in Pittsburgh from May 20 to 22. About Pratice Greenhealth Practice Greenhealth is the result of the merger of two leading organizations – Hospitals for a Healthy Environment (H2E) and the Green Guide for Health Care (GGHC) – with a new clean energy and energy efficiency program – Healthcare Clean Energy Exchange (HCEE). For more information on Practice Greenhealth, healthy initiatives, current trends, news and views, and other links to earth-friendly organizations, visit www.practicegreenhealth.org About TSO3 Founded in Québec, Canada, in 1998, TSO3 specializes in the research and development of innovative, high-performance medical instrument sterilization technology whit high commercial potential. The Company’s first product, the 125L Ozone Sterilizer is a low-temperature, high-capacity, general purpose sterilizer designed for medical facilities. This reliable, easy-to-use system provides safe, efficacious sterilization of heat and moisture-sensitive instruments. As a fast, economical and environmentally friendly technology, it can help hospitals control their costs and maintain a low inventory of medical devices. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications & IR (418) 651-0003, Ext. 237 ccote@tso3.com Stéphan Duchesne Sales and Marketing Director (418) 651-0003 Ext. 260 sduchesne@tso3.com Québec City, Canada, May 23, 2008 – TSO3 Inc. (www.tso3.com) has received the Champions for Change award from Practice Greenhealth (PGH), formerly Hospitals for a Healthy Environment (H2E), for the improvements made to its product for lower power requirements. This allows TSO3 to reduce the environmental footprint of its 125L Ozone Sterilizer and therefore, to assist its customers in improving their environmental performance.

“This award is a reflection of TSO3’s business ethics and represents a strong commitment to protect patient health and preserve the environment,” said Bob Jarboe, Executive Director, Practice Greenhealth. “The stakes are high and TSO3 has shown us their solutions are exciting.”

With this award, TSO3 gets recognition for its environmental initiatives for a second year in a row. In 2007, TSO3 was awarded the “Venture Green” mention at the 2007 OHA HealthAchieve show, held in Toronto for over 8,000 Healthcare Professionals.

“TSO3 recognizes the importance of providing quality medical products that also contribute to a better environment as one of our corporate commitments,” said W. Barry McDonald, Interim CEO for TSO3. “Many healthcare facilities are asking for eco-friendly, non-toxic products that eliminate/reduce the bio-hazard impact on employees and the environment. We are pleased to be delivering a unique sterilizer that can positively impact both the environment and public health. We are also pleased to receive this award as a confirmation of our commitment for better patient care with environmentally safe products.”

Practice Greenhealth presented Environmental Excellence awards to 140 organizations for their work and commitment to health care and the environment. The Awards were held on the first day of CleanMed 2008, a global conference for environmental leaders in health care, taking place in Pittsburgh from May 20 to 22.

About Pratice Greenhealth

Practice Greenhealth is the result of the merger of two leading organizations – Hospitals for a Healthy Environment (H2E) and the Green Guide for Health Care (GGHC) – with a new clean energy and energy efficiency program – Healthcare Clean Energy Exchange (HCEE). For more information on Practice Greenhealth, healthy initiatives, current trends, news and views, and other links to earth-friendly organizations, visit www.practicegreenhealth.org


About TSO3

Founded in Québec, Canada, in 1998, TSO3 specializes in the research and development of innovative, high-performance medical instrument sterilization technology whit high commercial potential.

The Company’s first product, the 125L Ozone Sterilizer is a low-temperature, high-capacity, general purpose sterilizer designed for medical facilities. This reliable, easy-to-use system provides safe, efficacious sterilization of heat and moisture-sensitive instruments. As a fast, economical and environmentally friendly technology, it can help hospitals control their costs and maintain a low inventory of medical devices.


- 30 -

Source: TSO3 Inc.

Information:

Caroline Côté
Director, Corporate Communications & IR
(418) 651-0003, Ext. 237
ccote@tso3.com

Stéphan Duchesne
Sales and Marketing Director
(418) 651-0003 Ext. 260
sduchesne@tso3.com
]]> NEWS FLASH - TSO3 Receives National Recognition for its Environmental Initiatives 2008-05-23 12:17:11 TSO3: First Quarter 2008 Financial Results http://www.tso3.com/en/news-events/news-tso3-first-quarter-2008-233.php Québec City, May 8, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces today the financial results for the first quarter of 2008. The Company recorded a net loss of $2,160,332 or $0.05 per share, compared to a net loss of $2,069,136 or $0.05 per share, for the same period in 2007. “I am pleased, with the support of the Board, to assume the position of interim President and Chief Executive Officer at TSO3 following the departure of Jocelyn Vézina, and to immediately evaluate and initiate the necessary actions that will lead to enhancing the Company’s revenue and market-share growth”, said W. Barry McDonald, Interim CEO for TSO3 Inc. “In regards to the initiatives to be undertaken in the short term, it is clear that TSO3 must count on a commercialization strategy that is better targeted to our primary market in North America. A realignment of sales and marketing resources to focus on market segmentation will increase our product penetration rate. Based on the strength of the sales record to date and the recent mandate of The Sage Group, we have identified the client profile to target in the very short term, which will allow us to be more effective. We will also look into the Company research and development program to ensure it is well adapted to the needs and expectations of other market segments we are targeting, and segments we wish to develop.” TSO3 will host a Conference Call at 12:00 P.M. (ET) today, May 8, 2008. Analysts and institutional investors are invited to participate. The numbers to dial for access are (514) 807-8791 (Montreal area), (416) 915 5763 (Toronto area) or the toll-free number 1-866-250-4892. Other Interested parties may listen to the live Webcast of the Conference Call accessible via TSO3’s Website at: www.tso3.com. The Webcast will be archived for 90 days. High Points of the Recent Months - Mandate to strategic committee composed of board directors and consultants at The Sage Group to re-evaluate the Company’s commercial strategy and ensure that both short-and long-term growth objectives are reached; - Closing of two very recent sales in the U.S. and re-evaluation of our efforts and resources to increase our sales growth in the coming months; - Signing of a multi-year agreement with Broadlane, a national group purchasing organization (GPO), serving hundreds of American healthcare organizations; - Promising preliminary results on the capacity of the 125L Ozone Sterilizer to deactivate prions, the infectious proteins that cause the Creuztfeld-Jakob Disease – the human version of mad cow disease, as part of ongoing research in England. To view the full announcement, click here. The full financial results will soon be available in the Investor's section of our Website. Québec City, May 8, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces today the financial results for the first quarter of 2008. The Company recorded a net loss of $2,160,332 or $0.05 per share, compared to a net loss of $2,069,136 or $0.05 per share, for the same period in 2007.

“I am pleased, with the support of the Board, to assume the position of interim President and Chief Executive Officer at TSO3 following the departure of Jocelyn Vézina, and to immediately evaluate and initiate the necessary actions that will lead to enhancing the Company’s revenue and market-share growth”, said W. Barry McDonald, Interim CEO for TSO3 Inc. “In regards to the initiatives to be undertaken in the short term, it is clear that TSO3 must count on a commercialization strategy that is better targeted to our primary market in North America. A realignment of sales and marketing resources to focus on market segmentation will increase our product penetration rate. Based on the strength of the sales record to date and the recent mandate of The Sage Group, we have identified the client profile to target in the very short term, which will allow us to be more effective. We will also look into the Company research and development program to ensure it is well adapted to the needs and expectations of other market segments we are targeting, and segments we wish to develop.”

TSO3 will host a Conference Call at 12:00 P.M. (ET) today, May 8, 2008. Analysts and institutional investors are invited to participate. The numbers to dial for access are (514) 807-8791 (Montreal area), (416) 915 5763 (Toronto area) or the toll-free number 1-866-250-4892.

Other Interested parties may listen to the live Webcast of the Conference Call accessible via TSO3’s Website at: www.tso3.com. The Webcast will be archived for 90 days.


High Points of the Recent Months

- Mandate to strategic committee composed of board directors and consultants at The Sage Group to re-evaluate the Company’s commercial strategy and ensure that both short-and long-term growth objectives are reached;

- Closing of two very recent sales in the U.S. and re-evaluation of our efforts and resources to increase our sales growth in the coming months;

- Signing of a multi-year agreement with Broadlane, a national group purchasing organization (GPO), serving hundreds of American healthcare organizations;

- Promising preliminary results on the capacity of the 125L Ozone Sterilizer to deactivate prions, the infectious proteins that cause the Creuztfeld-Jakob Disease – the human version of mad cow disease, as part of ongoing research in England.

To view the full announcement, click here.

The full financial results will soon be available in the Investor's section of our Website.
]]> TSO3: First Quarter 2008 Financial Results 2008-05-08 09:51:04 TSO3: Conference Call and Webcast - Financial Results for Q1 2008 http://www.tso3.com/en/news-events/news-tso3-conference-call-webcast-232.php Québec City, Canada, May 5, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) today announced that it will report financial results for the first quarter 2008 ended March 31, 2008, on Thursday, Mai 8, 2008. TSO3 will host a Conference Call at 12:00 P.M. (ET), on May 8, 2008. Analysts and institutional investors are invited to participate. The numbers to dial for access are (514) 807-8791 (Montréal area), (416) 915 5763 (Toronto area) or the toll-free number 1-866-250-4892. Other Interested parties may listen to the live Webcast of the Conference Call accessible via TSO3’s Website at: www.tso3.com. The Webcast will be archived for 90 days. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology whit high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. TSO3 currently has more than 72 employees, about half of whom work in the sales and marketing team. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications & IR (418) 651-0003, Ext. 237 Email: ccote@tso3.com Québec City, Canada, May 5, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) today announced that it will report financial results for the first quarter 2008 ended March 31, 2008, on Thursday, Mai 8, 2008.

TSO3 will host a Conference Call at 12:00 P.M. (ET), on May 8, 2008. Analysts and institutional investors are invited to participate. The numbers to dial for access are (514) 807-8791 (Montréal area), (416) 915 5763 (Toronto area) or the toll-free number 1-866-250-4892.

Other Interested parties may listen to the live Webcast of the Conference Call accessible via TSO3’s Website at: www.tso3.com. The Webcast will be archived for 90 days.


About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology whit high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment.

In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006.

TSO3 currently has more than 72 employees, about half of whom work in the sales and marketing team.

- 30 -

Source: TSO3 Inc.

Information:
Caroline Côté
Director, Corporate Communications & IR
(418) 651-0003, Ext. 237
Email: ccote@tso3.com
]]> TSO3: Conference Call and Webcast - Financial Results for Q1 2008 2008-05-05 12:55:27 BARRY McDONALD APPOINTED INTERIM CHIEF EXECUTIVE OFFICER OF TSO3 http://www.tso3.com/en/news-events/news-barry-mcdonald-appointed-231.php Jocelyn Vézina announces his departure as the Company’s CEO TSO3 creates a strategic committee and calls on the services of The Sage Group to review its commercial development strategy Québec City, May 1, 2008 – Germain Carrière, the Chairman of the Board of TSO3 Inc. (“TSO3”) (TSX: TOS), announces the appointment of W. Barry McDonald to the position of interim Chief Executive Officer for the Company. This appointment follows Jocelyn Vézina’s decision to leave his position as the Company’s CEO, a departure announced at the Company’s Annuel Shareholders Meeting held today in Québec City. “TSO3 is at a turning point in its history, where the Company is called upon to truly take flight commercially. After sincere reflection, it seemed clear to me that someone else, with a different profile and qualities, could better meet the current and future needs of TSO3. With no regrets, I am leaving the management of the business, more confident than ever in its future. Although the Company, inevitably, must meet new challenges, it can rely on solid assets, including an excellent team, quality patented technology and sufficient financial resources, to dynamically pursue its development activities, both in commercial and technological terms,” said Mr. Vézina. “I want to express our gratitude and appreciation for the outstanding work Jocelyn accomplished building TSO3. As he will remain active on the Company’s Board of Directors, it is not a separation, but rather a new form of collaboration. We are pleased to know that Jocelyn, through his passion, savoir-faire and expertise, can continue to contribute to the Company’s success,” said Mr. Carrière. Appointment of W. Barry McDonald To succeed Mr. Vézina, the Board of TSO3 has hired W. Barry McDonald, who is assuming the position of Chief Executive Officer for the Company on an interim basis. Mr. McDonald will temporarily leave his position as an Executive Director at The Sage Group, an American consulting firm. “Mr. McDonald, who was already acting as a consultant to TSO3, has over 35 years of experience in the healthcare industry. During his career, he has acted both as an executive and as a consultant. This appointment brings two significant advantages to TSO3: Mr. McDonald has deep knowledge of our markets and our sector of activity, plus he thoroughly understands the realities of our Company, which means he will be immediately operational in his new position. He is the man for the times, to ensure a smooth and productive transition at TSO3, from now until we proceed with recruiting a permanent CEO,” continued Mr. Carrière. Before joining The Sage Group, Mr. McDonald was, notably, chief executive officer at Mast/Hitachi, in addition to heading Hitachi Chemical, which oversaw business development and acquisitions at Hitachi Chemical’s life sciences business. Prior to that, Mr. McDonald was senior vice president, sales, marketing and business development at Hycor Biomedical, as well as president and CEO of Photest Diagnostics. Mr. McDonald also serves on the boards of directors for Healthcare Providers Direct, a publicly traded company, and Immunomic Therapeutics, a vaccine biotechnology company. Review of the commercial strategy In order to support the Company in its commercial development projects, the Board of Directors of TSO3 has formed a strategic committee composed of board directors and consultants at The Sage Group. The Board has mandated this committee to re-evaluate the Company’s commercial strategy to ensure that TSO3 can reach both its short- and long-term growth objectives. The Sage Group is a firm recognized for the quality of its international expertise in the healthcare industry, notably regarding marketing and business development. TSO3 has already used the services of this consulting firm several times in the past. “The Board was advised a few days ago of the strategic committee’s first recommendations. It is clear that TSO3 must focus on a better-targeted commercial strategy. We must better define market segments in order to target the niches where our business can offer an advantageous solution and respond to the needs of the targeted clienteles. In geographic terms, our priority market will be North America, particularly the United States,” Mr. Carrière pointed out. The strategic committee at TSO3 will also be looking at the Company’s research and development program to ensure that it is well adapted to the expectations and needs of the market segments targeted by the Company, or markets TSO3 would like to develop. “For TSO3, our technology development activities of the future will continue to play a crucial role in the Company’s growth. Consequently, we intend to increase our investments in this area in the short and medium terms,” concluded Mr. Carrière. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centres in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green,” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low-temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the U.S. Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. TSO3 currently has more than 72 employees, about half of whom work in the sales and marketing team. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications & IR (418) 651-0003, Ext. 237 Email: ccote@tso3.com Jocelyn Vézina announces his departure as the Company’s CEO

TSO3 creates a strategic committee and calls on the services of
The Sage Group to review its commercial development strategy


Québec City, May 1, 2008 – Germain Carrière, the Chairman of the Board of TSO3 Inc. (“TSO3”) (TSX: TOS), announces the appointment of W. Barry McDonald to the position of interim Chief Executive Officer for the Company. This appointment follows Jocelyn Vézina’s decision to leave his position as the Company’s CEO, a departure announced at the Company’s Annuel Shareholders Meeting held today in Québec City.

“TSO3 is at a turning point in its history, where the Company is called upon to truly take flight commercially. After sincere reflection, it seemed clear to me that someone else, with a different profile and qualities, could better meet the current and future needs of TSO3. With no regrets, I am leaving the management of the business, more confident than ever in its future. Although the Company, inevitably, must meet new challenges, it can rely on solid assets, including an excellent team, quality patented technology and sufficient financial resources, to dynamically pursue its development activities, both in commercial and technological terms,” said Mr. Vézina.

“I want to express our gratitude and appreciation for the outstanding work Jocelyn accomplished building TSO3. As he will remain active on the Company’s Board of Directors, it is not a separation, but rather a new form of collaboration. We are pleased to know that Jocelyn, through his passion, savoir-faire and expertise, can continue to contribute to the Company’s success,” said Mr. Carrière.

Appointment of W. Barry McDonald

To succeed Mr. Vézina, the Board of TSO3 has hired W. Barry McDonald, who is assuming the position of Chief Executive Officer for the Company on an interim basis. Mr. McDonald will temporarily leave his position as an Executive Director at The Sage Group, an American consulting firm.

“Mr. McDonald, who was already acting as a consultant to TSO3, has over 35 years of experience in the healthcare industry. During his career, he has acted both as an executive and as a consultant. This appointment brings two significant advantages to TSO3: Mr. McDonald has deep knowledge of our markets and our sector of activity, plus he thoroughly understands the realities of our Company, which means he will be immediately operational in his new position. He is the man for the times, to ensure a smooth and productive transition at TSO3, from now until we proceed with recruiting a permanent CEO,” continued Mr. Carrière.

Before joining The Sage Group, Mr. McDonald was, notably, chief executive officer at Mast/Hitachi, in addition to heading Hitachi Chemical, which oversaw business development and acquisitions at Hitachi Chemical’s life sciences business. Prior to that, Mr. McDonald was senior vice president, sales, marketing and business development at Hycor Biomedical, as well as president and CEO of Photest Diagnostics. Mr. McDonald also serves on the boards of directors for Healthcare Providers Direct, a publicly traded company, and Immunomic Therapeutics, a vaccine biotechnology company.

Review of the commercial strategy

In order to support the Company in its commercial development projects, the Board of Directors of TSO3 has formed a strategic committee composed of board directors and consultants at The Sage Group. The Board has mandated this committee to re-evaluate the Company’s commercial strategy to ensure that TSO3 can reach both its short- and long-term growth objectives.

The Sage Group is a firm recognized for the quality of its international expertise in the healthcare industry, notably regarding marketing and business development. TSO3 has already used the services of this consulting firm several times in the past.

“The Board was advised a few days ago of the strategic committee’s first recommendations. It is clear that TSO3 must focus on a better-targeted commercial strategy. We must better define market segments in order to target the niches where our business can offer an advantageous solution and respond to the needs of the targeted clienteles. In geographic terms, our priority market will be North America, particularly the United States,” Mr. Carrière pointed out.

The strategic committee at TSO3 will also be looking at the Company’s research and development program to ensure that it is well adapted to the expectations and needs of the market segments targeted by the Company, or markets TSO3 would like to develop. “For TSO3, our technology development activities of the future will continue to play a crucial role in the Company’s growth. Consequently, we intend to increase our investments in this area in the short and medium terms,” concluded Mr. Carrière.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centres in the hospital environment.

In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green,” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low-temperature sterilization processes currently used in hospitals.

The 125L Ozone Sterilizer is cleared for commercialization by the U.S. Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006.

TSO3 currently has more than 72 employees, about half of whom work in the sales and marketing team.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

- 30 -

Source: TSO3 Inc.

Information:

Caroline Côté
Director, Corporate Communications & IR
(418) 651-0003, Ext. 237
Email: ccote@tso3.com
]]> BARRY McDONALD APPOINTED INTERIM CHIEF EXECUTIVE OFFICER OF TSO3 2008-05-01 11:01:00 TSO3 Sells its 28th Ozone Sterilizer to a Major Healthcare System http://www.tso3.com/en/news-events/news-tso3-sells-its-28th-ozone-230.php Québec City, Qc, Canada, May 1st, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces its 28th sale, this time to an American healthcare system in the South East. This sale is the second one to occur early in the quarter. This most recent sale was made to a healthcare system which is a leader in its region, providing care to two million residents and to international visitors as well. Its location in a large southeastern city provides TSO3 with an additional commercial window to showcase the 125L Ozone Sterilizer to potential customers. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. TSO3 currently has more than 72 employees, about half of whom work in the sales and marketing team. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications & IR (418) 651-0003, Ext. 237 Email: ccote@tso3.com Québec City, Qc, Canada, May 1st, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces its 28th sale, this time to an American healthcare system in the South East. This sale is the second one to occur early in the quarter.

This most recent sale was made to a healthcare system which is a leader in its region, providing care to two million residents and to international visitors as well. Its location in a large southeastern city provides TSO3 with an additional commercial window to showcase the 125L Ozone Sterilizer to potential customers.


About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment.

In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006.

TSO3 currently has more than 72 employees, about half of whom work in the sales and marketing team.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

- 30 -

Source: TSO3 Inc.

Information:

Caroline Côté
Director, Corporate Communications & IR
(418) 651-0003, Ext. 237
Email: ccote@tso3.com
]]> TSO3 Sells its 28th Ozone Sterilizer to a Major Healthcare System 2008-05-01 11:00:00 TSO3 to hold Annual and Special Meeting of Shareholders May 1, 2008 http://www.tso3.com/en/news-events/news-tso3-hold-annual-special-229.php Quebec City, April 23, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) will hold its fiscal 2007 Annual and Special Meeting of Shareholders on Thursday, May 1, 2008. The meeting will be held at the Musée National des Beaux-Arts du Québec, Salon Paul-Rainville, 1st avenue Wolfe-Montcalm, Quebec City at 10:30 A.M. (ET). For those who are unable to attend in person, a webcast of the meeting and management presentation will be accessible from TSO3's website at www.tso3.com. On this occasion, Mr. Jocelyn Vézina, CEO of TSO3 and the other management team members, will provide an update on the current situation, as well as on development projects. About TSO3 TSO3, founded in Quebec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 has been in the commercialization phase for this first product since 2006. TSO3 currently has more than 72 employees, about half of whom work in the sales and marketing team. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications & IR (418) 651-0003, Ext. 237 Email: ccote@tso3.com Quebec City, April 23, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) will hold its fiscal 2007 Annual and Special Meeting of Shareholders on Thursday, May 1, 2008. The meeting will be held at the Musée National des Beaux-Arts du Québec, Salon Paul-Rainville, 1st avenue Wolfe-Montcalm, Quebec City at 10:30 A.M. (ET). For those who are unable to attend in person, a webcast of the meeting and management presentation will be accessible from TSO3's website at www.tso3.com.

On this occasion, Mr. Jocelyn Vézina, CEO of TSO3 and the other management team members, will provide an update on the current situation, as well as on development projects.


About TSO3

TSO3, founded in Quebec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment.

In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 has been in the commercialization phase for this first product since 2006.

TSO3 currently has more than 72 employees, about half of whom work in the sales and marketing team.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
- 30 -
Source: TSO3 Inc.

Information:
Caroline Côté
Director, Corporate Communications & IR
(418) 651-0003, Ext. 237
Email: ccote@tso3.com
]]> TSO3 to hold Annual and Special Meeting of Shareholders May 1, 2008 2008-04-23 14:52:14 TSO3 Closes a 27th Sale of a 125L Ozone Sterilizer http://www.tso3.com/en/news-events/news-tso3-closes-27th-sale-125l-228.php Québec City, Qc, Canada, April 4th, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces the sale of a 27th unit to date, to an American hospital renowned for being the only Level 1 Trauma center in its state. This hospital is a large university teaching hospital in the Southeastern U.S., which was previously dependent on Ethylene Oxide for its low temperature sterilization needs, and had environmental concerns with that method. They were attracted to ozone sterilization because it would allow them to improve their environmental practices. “This hospital is the perfect example of the type of organization that we are currently targeting with our 125L Ozone Sterilizer and where we are a perfect fit. This hospital was looking to improve their environmental footprint, while reducing cost and benefiting from a faster turnaround time of their medical instrumentation”, stated Jocelyn Vézina CEO. “We anticipate several more of this type of account to turn into sales during the year. As it has been our experience so far, we believe that sales should be more heavily weighted in the second semester of the year.” About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology whit high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. TSO3 currently has more than 72 employees, about half of whom work in the sales and marketing team. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications & IR (418) 651-0003, Ext. 237 Email: ccote@tso3.com Québec City, Qc, Canada, April 4th, 2008 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces the sale of a 27th unit to date, to an American hospital renowned for being the only Level 1 Trauma center in its state.

This hospital is a large university teaching hospital in the Southeastern U.S., which was previously dependent on Ethylene Oxide for its low temperature sterilization needs, and had environmental concerns with that method. They were attracted to ozone sterilization because it would allow them to improve their environmental practices.

“This hospital is the perfect example of the type of organization that we are currently targeting with our 125L Ozone Sterilizer and where we are a perfect fit. This hospital was looking to improve their environmental footprint, while reducing cost and benefiting from a faster turnaround time of their medical instrumentation”, stated Jocelyn Vézina CEO. “We anticipate several more of this type of account to turn into sales during the year. As it has been our experience so far, we believe that sales should be more heavily weighted in the second semester of the year.”


About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology whit high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment.

In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006.

TSO3 currently has more than 72 employees, about half of whom work in the sales and marketing team.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

- 30 -

Source: TSO3 Inc.

Information:

Caroline Côté
Director, Corporate Communications & IR
(418) 651-0003, Ext. 237
Email: ccote@tso3.com
]]> TSO3 Closes a 27th Sale of a 125L Ozone Sterilizer 2008-04-04 07:15:36